Información de la revista
Vol. 111. Núm. 8.
Páginas 704-705 (octubre 2020)
Vol. 111. Núm. 8.
Páginas 704-705 (octubre 2020)
Case and Research Letters
Open Access
Effectiveness of Certolizumab Pegol in the Treatment of Psoriasis in a Cohort of Patients With Psoriatic Arthritis
Efectividad de certolizumab pegol en psoriasis en una cohorte de pacientes con artritis psoriásica
D. Reinaa, D. Vidalb,
Autor para correspondencia

Corresponding author.
a Servicio de Reumatología, Hospital Moisès Broggi de Sant Joan Despí, Barcelona, Spain
b Servicio de Dermatología, Hospital Moisès Broggi de Sant Joan Despí, Barcelona, Spain
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Texto completo
Descargar PDF
Tablas (1)
Table 1. Change in Psoriasis severity during treatment as assessed with the IGA Mod 2011 5-Point Scale.
Texto completo
Dear Editor:

Certolizumab pegol (CZP) is an anti-TNF agent that has been recently approved for the treatment of moderate to severe plaque psoriasis in adults.1 Rheumatologists, in contrast, have been using the drug in psoriatic arthritis since 2012.2 To assess the effectiveness of CZP in plaque psoriasis, a retrospective observational, multicenter study was conducted in patients treated for psoriatic arthritis who had active plaque psoriasis at the time of treatment initiation. The severity of psoriatic arthritis was assessed using the Disease Activity Score (DAS) 28 while plaque psoriasis was assessed with the 2011 modification of the Investigator Global Assessment (IGA mod 2011) scale (5-point physical global evaluation: 0, clear; 1, almost clear; 2, mild disease; 3, moderate disease; and 4, severe disease).3

The study included 22 adult patients, 16 women (73%) and 6 men (2%), from 4 hospitals in the same province of Spain. The mean duration of plaque psoriasis and psoriatic arthritis was 16 and 12 years, respectively. All patients were diagnosed with psoriatic arthritis according to the CASPAR criteria4 and plaque psoriasis. Nineteen patients had (86%) peripheral psoriatic arthritis, 15 (68%) polyarticular psoriatic arthritis, 13 (59%) dactylitis, 12 (55%) axial psoriatic arthritis, and 12 (55%) ungual psoriasis. Eighteen patients (81%) had received prior biologic therapy, and the regimen for CZP was the usual one for psoriatic arthritis in all cases: 400 mg administered subcutaneously at weeks 0, 2, and 4, followed by 200 mg every 2 weeks.

On starting treatment, mean DAS28 was 5.79 and all patients had active plaque psoriasis (IGA mod 2011 ≥ 1): almost clear in 4 (18%), mild in 11 (50%), and moderate-severe in 7 patients (32%) (Table 1).

Table 1.

Change in Psoriasis severity during treatment as assessed with the IGA Mod 2011 5-Point Scale.

IGA mod 2011  Treatment Initiation  6 Months Treatment  12 Months Treatment 
0%  32%  25% 
18%  41%  50% 
11  50%  18%  17% 
9%  5%  0% 
23%  5%  8% 
Total  22    22    12   

After 6 months treatment with CZP, mean DAS28 was 3.4 and the severity of plaque psoriasis improved significantly: 16 patients (72%) were clear or almost clear of lesions, 4 (18%) had mild disease, and 2 (10%) had moderate-severe disease. After 12 months, only 12 patients had an IGA mod 2011 assessment: 9 patients (75%) were clear or almost clear of lesions, 2 (17%) had mild disease, and 1 (8%) had severe disease; and the mean DAS28 was 3.71. The statistical analysis showed significant differences (P < .05) between baseline IGA mod 2011 and that observed at 6 and 12 months, as well as a correlation between the DAS28 and IGA mod 2011 scales.

The present study has several biases and limitations, such as a small sample size and a sample comprising patients who had already received prior biologic therapy. In addition, the scale for assessing plaque psoriasis is the IGA mod 2011, given that the Psoriasis Area Severity Index is not a scale used in everyday clinical practice by rheumatologists. Despite these limitations, this study confirms a high degree of effectiveness for CZP in plaque psoriasis in patients with psoriatic arthritis, and so this agent should be considered when treating patients who present with psoriatic arthritis and moderate-severe plaque psoriasis simultaneously.

Conflicts of interest

Reina D and Vidal D have received speaker fees from UCB Pharma.


We would like to thank Drs. L. Mateo, A. Prior, A. Laíz, and M. Moreno for their collaboration in this study.

M. Lebwohl, A. Blauvelt, C. Paul, H. Sofen, J. Węgłowska, V. Piguet, et al.
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
J Am Acad Dermatol, 79 (2018), pp. 266-276
P.J. Mease, R. Fleischmann, A.A. Deodhar, J. Wollenhaupt, M. Khraishi, D. Kielar, et al.
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
Ann Rheum Dis, 73 (2014), pp. 48-55
R.G. Langley, S.R. Feldman, J. Nyirady, P. van de Kerkhof, C. Papavassilis.
The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.
J Dermatolog Treat, 26 (2015), pp. 23-31
W. Taylor, D. Gladman, P. Helliwell, A. Marchesoni, P. Mease, H. Mielants.
Classification criteria for psoriatic arthritis: development of new criteria from a large international study.
Arthritis Rheum, 54 (2006), pp. 2665-2673

Please cite this article as: Reina D, Vidal D. Efectividad de certolizumab pegol en psoriasis en una cohorte de pacientes con artritis psoriásica. Actas Dermosifiliogr. 2020.

Copyright © 2020. AEDV
Actas Dermo-Sifiliográficas
Opciones de artículo
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?